Loading…
← CockpitCompetitor Analysis › 0874.HK Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class HOpen in the cockpit ↗

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H0874.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Large Chinese pharma group making traditional Chinese medicine and generic drugs, with a nationwide pharmacy retail/distribution network.

≈ A Chinese CVS Health plus a generic-drug makerMomentum neutral 42
Mkt cap
$4.48B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$1.72M
20-day average traded
Fwd P/E
7.0×
forward earnings
ROIC−WACC
-1.5 pp
WACC 6.1%
Hurdle
-3 pp
Req g minus delivered
Next earnings
114 days
12 Mar 2027
Close · HKDHK$12.55
1D-0.1%
1W-2.1%
1M-4.3%
3M-16.8%
6M-22.6%
YTD-29.2%
1Y-36.7%
ATR %1.7%
52w lowhigh38.5% off high

What Guangzhou Baiyunshan Pharmaceutical does

Large Chinese pharma group making traditional Chinese medicine and generic drugs, with a nationwide pharmacy retail/distribution network.

Distribution of other makers' drugs brings in a large share of revenue but little of the profit, while its own traditional-medicine and generic-drug factories, the pharmacy chain and the Wanglaoji herbal-tea brand carry the margins. This is the Hong Kong listing of the company trading in Shanghai as 600332.SS. Guangzhou's state-owned pharmaceutical group controls it.

In one line: A Chinese CVS Health plus a generic-drug maker.

Products and services

  • Traditional Chinese medicine products
  • Generic pharmaceuticals
  • Pharmacy retail chain
  • Pharma distribution

Customers

  • Retail consumers
  • Hospitals
  • Pharmacies

Where it sits in the supply chain

  • Pharmaceuticals
  • TCM & generic manufacturing
  • Pharmacy retail/distribution

What could go right

  • China healthcare consumption growth
  • Retail pharmacy expansion

What could go wrong

  • Drug price controls / centralized procurement
  • Low-margin distribution business

Moat: narrow (brand, distribution, scale). Century-old TCM brands and one of China's largest pharmacy distribution networks.

Headquarters: Guangzhou, China · Founded: 1997 · Employees: 27,057

Named competitors

Guangzhou Baiyunshan Pharmaceutical at a glance

Size Guangzhou Baiyunshan Pharmaceutical (0874.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $4.48B, the 268th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$12.55 on 18 Nov 2026.

Performance Over six months the shares fell 22.6%, against +10.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue grew 6.0% over the last twelve months (peer median +10.2%); the operating margin is 3.1% (peer median 17.1%).

Valuation It trades at 7.0× forward earnings against a peer median of 29.9× (cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -3 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.5 points below its cost of capital (6.1% WACC).

Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 1110874.HK 78
Six months, rebased to 100: Guangzhou Baiyunshan Pharmaceutical against the median of its 20 peers (local-currency closes).

Guangzhou Baiyunshan Pharmaceutical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$88.8BHK$84.0BHK$81.1BHK$83.1BHK$82.0B
Revenue growth—+4%-2%+1%—
Gross profitHK$13.8BHK$12.8BHK$12.7BHK$14.6BHK$14.4B
EBITDAn/aHK$4.40BHK$4.65BHK$6.01BHK$5.59B
Net incomeHK$2.47BHK$3.24BHK$3.07BHK$4.48BHK$4.61B
Free cash flowHK$1.59B-HK$1.06BHK$2.74BHK$3.16BHK$6.78B
Capital expenditureHK$1.24BHK$1.34BHK$1.22BHK$1.80BHK$1.61B
Total debtHK$27.2BHK$23.0BHK$19.7BHK$17.4BHK$17.7B

Quarterly statements and history in the cockpit →

Guangzhou Baiyunshan Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%0%+50%IONSAJANTPHARM600566CAMX002294EMCUREGLAXOTVTXERAS4536000100600085DFTX326030LQDA1289400874.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Guangzhou Baiyunshan Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×AJANTPHARM600566CAMX002294EMCUREGLAXOTVTX600079000100600085326030LQDA0874.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guangzhou Baiyunshan Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%+200%0%100%200%AJANTPHARM600566CAMX002294EMCURE4536PTCT326030LQDA3015690874.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Guangzhou Baiyunshan Pharmaceutical is the large dot.

Guangzhou Baiyunshan Pharmaceutical competitors and peer comparison

Head to head with its named competitors (0874.HK vs 3320.HK vs 000538.SZ vs 0867.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Guangzhou Baiyunshan Pharmaceutical 0874.HK$4.48B-23%+6%3%7.0×1.3%
China Resources Pharmaceutical 3320.HK$3.60B-7%+8%4%5.8×-4.9%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%
China Medical System 0867.HK$2.95B-15%+15%20%9.8×1.1%

How Guangzhou Baiyunshan Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guangzhou Baiyunshan Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure0874.HKPeer medianRank in peer set
1-month return-4.3%+0.7%7th lowest of 21
6-month return-22.6%+10.4%3rd lowest of 20
Distance from 52-week high-38.5%-32.7%8th lowest of 21
Revenue growth (TTM)+6.0%+10.2%9th lowest of 19
Operating margin3.1%17.1%3rd lowest of 19
Forward P/E7.0×29.9×cheapest of 17
Growth the price implies (Req g, 7 yrs)1.3%7.3%5th least demanding of 17
Growth delivered (Del g)+4.0%+10.9%5th lowest of 17
Hurdle (Req g minus delivered)-2.7 pp-3.7 pp8th most demanding of 17
ROIC minus cost of capital-1.5 pp+5.6 pp4th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Guangzhou Baiyunshan Pharmaceutical 0874.HKHong Kong$4.48B-23%+6%3%7.0×1.3%+4.0%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%16.7×-5.0%+3.2%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%

Questions

Who are Guangzhou Baiyunshan Pharmaceutical's main competitors?
Named competitors: China Resources Pharmaceutical (3320.HK), Yunnan Baiyao (000538.SZ), China Medical System (0867.HK). The cockpit's measured peer set (industry) also includes Ionis Pharmaceuticals (IONS), Ajanta Pharma (AJANTPHARM.NS), HUBEI JUMPCAN PHARMACEUTICAL (600566.SS), Camurus (CAMX.ST), Shenzhen Salubris Pharmaceuticals (002294.SZ), Emcure Pharmaceuticals (EMCURE.NS).
Is Guangzhou Baiyunshan Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 7.0× against a peer median of 29.9×, cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -3 pp: the price already allows for a slowdown.
How has Guangzhou Baiyunshan Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -22.6% against +10.4% for the median peer; over one year -36.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.